Price movement over the last 24 hours
Ambarella Inc vs Tilray Brands Inc — how do they compare? Ambarella Inc trades at $75.39 (market cap $3.39B), while Tilray Brands Inc trades at $4.5 (market cap $544.44M). The key difference: Ambarella Inc is far larger — about 6.2× Tilray Brands Inc's market cap, and Ambarella Inc is trading nearer its 52-week high, Tilray Brands Inc nearer its low. Which is the better fit depends on your goals.
| AMBA | TLRY | |
|---|---|---|
Market Cap | $3.39B | $544.44M |
Sector | Technology | Health |
52-Week High | $95.51 | $21.00 |
52-Week Low | $48.65 | $4.31 |
Enterprise Value | $3.13B | $641.59M |
Signals from Pluang's Aura AI — not financial advice
Ambarella (AMBA) trades at $77.30, down 1.38% on the day, with a bullish technical setup supported by moving averages and key resistance at $81. The company reported three consecutive quarterly EPS beats, with Q1 2027 earnings of $0.11 meeting estimates, while revenue grew 16.9% year-over-year to $100.4 million. A major catalyst is the $800+ million long-term edge AI agreement with Hanwha, signaling strong demand in physical AI markets. However, net income remains negative at -$117.13 million for 2025, though margins are improving.
Outlook: Wall Street is bullish with a $108.67 consensus price target (40% upside), driven by edge AI adoption and auto sector growth. Risks include persistent losses, competitive pressure from larger chipmakers, and execution challenges in scaling new AI contracts. The stock's valuation at 8.21x sales appears reasonable if revenue acceleration continues, but profitability remains key for sustained gains.
TLRY trades at $4.42, up 0.68% on the day, with a bearish technical outlook and mixed fundamentals. The stock shows low valuation ratios (P/S 0.55, P/B 0.35) but deep losses (net margin -156.67%) and negative cash flow from operations. Recent news highlights expansion in medical cannabis and new product launches, yet earnings misses and high debt-to-asset ratios signal ongoing challenges.
Outlook remains uncertain with profitability elusive; growth via acquisitions adds scale but not earnings. Analyst consensus is cautious (25% buy, 65% hold), reflecting skepticism about near-term turnaround. Key risks include sustained cash burn, competitive pressures, and regulatory hurdles in the cannabis sector.
Trailing returns across standard periods
Latest headlines on both assets
Ambarella is a semiconductor company specializing in low-power video compression and computer vision processors. Its chips power AI cameras for security, automotive safety, and robotics applications.
Read more on AMBA →Tilray is a Canadian company that grows and sells medical and recreational cannabis. In 2021, Aphria acquired Tilray in a reverse merger and adopted the Tilray name. Most of its sales come from Canada and international medical cannabis exports, while its U.S. business focuses on CBD products and alcohol.
Read more on TLRY →